---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-014916"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:26:20.887170+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ProMIS Q2 net loss $2.3M; cash drops to $1.2M; PMN310 IND cleared

## Summary
- Net loss $2.3M vs $2.7M YoY; R&D expense fell to $1.0M from $3.2M.
- Cash and equivalents $1.2M at June 30, 2023, down from $5.9M at Dec 31, 2022.
- PMN310 received FDA IND clearance in May 2023; Phase 1a planned subject to capital.
- Preclinical data at AAIC 2023 showed PMN310 selectively targets toxic amyloid beta oligomers with potential for improved safety.
- Shares delisted from TSX in July 2023; now trades solely on Nasdaq.

## SEC filing metadata
- accession: 0001558370-23-014916
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837023014916/0001558370-23-014916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837023014916/pmn-20230814x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-014916
- JSON: https://secwatch.observer/filing/0001558370-23-014916.json
- Plain text: https://secwatch.observer/filing/0001558370-23-014916.txt

## Key facts
- Earnings Releases
  ProMIS Neurosciences Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $2.3 million for the quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Net income: Net loss was $2.3 million for the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 14, 2023, ProMIS Neurosciences Inc. (the "Company") issued a press release, which is available on its website (www.promisneurosciences.com under “Investors/Financial Results”), reporting its financial condition and financial results as of and for the three and six months ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374339/000155837023014916/0001558370-23-014916-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.